Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is pioneering a strategy that combines three emerging frontiers in cancer drug development: novel DNA damage response (DDR) targeting, advanced nanoparticle drug delivery, and artificial intelligence. This integrated approach aims to tackle persistent challenges such as tumor resistance, costly trial failures, and poor drug bioavailability.
The company’s lead candidate, ONC010, is a PNKP inhibitor—a DDR target distinct from PARP. By inhibiting PNKP, ONC010 disrupts cancer cells’ ability to repair DNA damage caused by radiation or chemotherapy, potentially overcoming resistance mechanisms that limit the efficacy of existing treatments. ONC010 is encapsulated in a proprietary nanoparticle delivery system designed to enhance tumor targeting and reduce systemic toxicity.
Complementing its biological and delivery innovations, Onco-Innovations leverages AI through its Inka Health subsidiary and the SynoGraph causal AI platform. These tools are intended to improve patient stratification, optimize clinical trial design, and generate real-world evidence, addressing the high failure rate and cost of oncology trials. The company is currently advancing ONC010 through IND-enabling studies, manufacturing, and regulatory preparations.
According to the press release, the integration of these technologies positions Onco-Innovations to address three persistent problems in cancer drug development: tumors evolving resistance, expensive and often unsuccessful clinical trials due to poor patient selection, and the failure of promising drugs to reach patients because of toxicity or delivery challenges. By treating these issues as interconnected, the company aims to create a more efficient development pathway.
For more information, visit the company’s newsroom at ibn.fm/ONNVF. The company’s recent updates are available through InvestorWire, a specialized communications platform. The full terms of use and disclaimers can be found at InvestorWire.com/Disclaimer.
